Novartis brings BeiGene's promising checkpoint inhibitor into the fold, but what about highly touted spartalizumab?
Arriving on the Chinese market among a wave of PD-1 checkpoint inhibitors in late 2019, BeiGene’s tislelizumab has earned laurels for its outstanding data and broad pipeline. Now, Novartis has signed a deal to take BeiGene’s drug abroad in what could be seen as a snub for its own touted in-house PD-1 antibody.
Novartis will drop $650 million in upfront cash for commercial and co-development rights to most major markets outside of China for tislelizumab, a PD-1 checkpoint inhibitor that already sports marketing approval in China for non-Hodgkin’s lymphoma and metastatic urothelial carcinoma, the Swiss drugmaker said Monday.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 148,400+ biopharma pros reading Endpoints daily — and it's free.